Clinical Trial Update: Ulinastatin Treatment Reduces the Incidence of Sepsis-associated Encephalopathy

View source ↗

Summary

A completed clinical trial indicates that ulinastatin treatment reduces the incidence of sepsis-associated encephalopathy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sepsis-associated Encephalopathy

Drugs mentioned

• Ulinastatin (ulinastatin)

Snippet

Sponsor: Shusheng Li | Conditions: Sepsis-Associated Encephalopathy | Status: COMPLETED